Calcipotriene/Betamethasone Dipropionate Cream vs Calcipotriene/Betamethasone Dipropionate Foam

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: Vitamin D receptor + Glucocorticoid receptor · full Psoriasis pipeline

Calcipotriene/Betamethasone Dipropionate Cream · Wynzora

Marketed by MC2 Therapeutics

Approved in Psoriasissmall molecule
Partial signal

NCT03308799 · Phase 3 · completed

This randomized, investigator-blind Phase 3 trial gave calcipotriene/betamethasone dipropionate cream (MC2-01, Wynzora), CAL/BDP topical suspension or cream vehicle once daily for 8 weeks to 796 patients with psoriasis. The primary endpoint was PGA treatment success at week 8. The cream was significantly better than both the topical suspension (37.4% vs 22.8%) and the vehicle (3.7%), each P<0.0001, so the primary was met. Source: the peer-reviewed paper (Stein Gold et al., J Drugs Dermatol 2021), which cites this NCT number.

Reported efficacy

Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score (8 Weeks): Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score (8 Weeks): MC2-01 Cream -67.5% (Standard Error 20.8) vs Cal/BDP Combination -63.5% (Standard Error 22.2) vs Vehicle -11.7% (Standard Error 21.9) (unclear)

Result source: NCT03802344

Calcipotriene/Betamethasone Dipropionate Foam · Enstilar

Marketed by LEO Pharma

Approved in Psoriasissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointCalcipotriene/​Betamethasone Dipropionate CreamCalcipotriene/​Betamethasone Dipropionate Foam
PASI 75—Not reported50% vs 14.3%+35.7 vs placebowk 16 · n 14NCT03441789
2 other results
  • 28.6% vs 14.3% wk 12 · n 14 · Phase 4 · secondary NCT03441789
  • 50% vs 7.1% wk 4 · n 14 · Phase 4 · secondary NCT03441789
PASI 90—Not reported—Not posted · NCT03731091
PASI 100—Not reported—Not posted · NCT03731091
sPGA 0/1—Not reported—Not posted · NCT03731091
DLQI, change—Not reported3 vs 6−3 vs placebowk 16 · n 14NCT03441789
5 other results
  • 5 vs 5 wk 12 · n 14 · Phase 4 · secondary NCT03441789
  • -6.4 vs -7.2 wk 8 · n 19 · Phase 4 · secondary NCT03506477
  • -6.5 vs -6.8 wk 4 · n 19 · Phase 4 · secondary NCT03506477
  • 2 vs 5 wk 4 · n 14 · Phase 4 · secondary NCT03441789
  • -4.4 vs -11.3 wk 2 · n 19 · Phase 4 · secondary NCT03506477

PASI 75

Calcipotriene/​Betamethasone Dipropionate Cream
—Not reported
Calcipotriene/​Betamethasone Dipropionate Foam
50% vs 14.3%+35.7 vs placebowk 16 · n 14NCT03441789
2 other results
  • 28.6% vs 14.3% wk 12 · n 14 · Phase 4 · secondary NCT03441789
  • 50% vs 7.1% wk 4 · n 14 · Phase 4 · secondary NCT03441789

PASI 90

Calcipotriene/​Betamethasone Dipropionate Cream
—Not reported
Calcipotriene/​Betamethasone Dipropionate Foam
—Not posted · NCT03731091

PASI 100

Calcipotriene/​Betamethasone Dipropionate Cream
—Not reported
Calcipotriene/​Betamethasone Dipropionate Foam
—Not posted · NCT03731091

sPGA 0/1

Calcipotriene/​Betamethasone Dipropionate Cream
—Not reported
Calcipotriene/​Betamethasone Dipropionate Foam
—Not posted · NCT03731091

DLQI, change

Calcipotriene/​Betamethasone Dipropionate Cream
—Not reported
Calcipotriene/​Betamethasone Dipropionate Foam
3 vs 6−3 vs placebowk 16 · n 14NCT03441789
5 other results
  • 5 vs 5 wk 12 · n 14 · Phase 4 · secondary NCT03441789
  • -6.4 vs -7.2 wk 8 · n 19 · Phase 4 · secondary NCT03506477
  • -6.5 vs -6.8 wk 4 · n 19 · Phase 4 · secondary NCT03506477
  • 2 vs 5 wk 4 · n 14 · Phase 4 · secondary NCT03441789
  • -4.4 vs -11.3 wk 2 · n 19 · Phase 4 · secondary NCT03506477
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Calcipotriene/Betamethasone Dipropionate Cream: 3 of 4 rows · Calcipotriene/Betamethasone Dipropionate Foam: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCalcipotriene/​Betamethasone Dipropionate CreamCalcipotriene/​Betamethasone Dipropionate Foam
Dropout rate
8.3%
NCT03308799 · Phase 3 · Psoriasis · phase 3
show 1 more result
3.8%
NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3
50%a
NCT04227288 · Phase 4 · registry result, not featured evidence
show 3 more results
5%
NCT03506477 · Phase 4 · registry result, not featured evidence
0%
NCT03848871 · Phase 4 · registry result, not featured evidence
7.1%
NCT03441789 · Phase 4 · registry result, not featured evidence · combination
Discontinued due to AEs
—
NCT03308799 · Phase 3 · Psoriasis · phase 3
show 1 more result
—
NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3
—a
NCT04227288 · Phase 4 · registry result, not featured evidence
show 3 more results
—
NCT03506477 · Phase 4 · registry result, not featured evidence
—
NCT03848871 · Phase 4 · registry result, not featured evidence
0%
NCT03441789 · Phase 4 · registry result, not featured evidence · combination
Serious AEs
3.3%
NCT03308799 · Phase 3 · Psoriasis · phase 3
show 1 more result
0.5%
NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3
0%a
NCT04227288 · Phase 4 · registry result, not featured evidence
show 3 more results
0%
NCT03506477 · Phase 4 · registry result, not featured evidence
0%
NCT03848871 · Phase 4 · registry result, not featured evidence
7.1%
NCT03441789 · Phase 4 · registry result, not featured evidence · combination
Most frequent reported AEs
nasopharyngitis 4.7% (placebo 1.5%)
NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3
a
sinusitis 16.7%
torn bicep 16.7%
torn rotator cuff 16.7%
NCT04227288 · Phase 4 · registry result, not featured evidence
show 3 more results
common cold 15% (placebo 0%)
diarrhea 10% (placebo 0%)
upper extremity pain 10% (placebo 0%)
NCT03506477 · Phase 4 · registry result, not featured evidence
dry cough 5%
gerd exacerbation 5%
NCT03848871 · Phase 4 · registry result, not featured evidence
rhinorrhea 14.3% (placebo 0%)
abdominal cramping 7.1% (placebo 0%)
chest congestion 7.1% (placebo 0%)
NCT03441789 · Phase 4 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Calcipotriene/Betamethasone Dipropionate Cream

PGA 2-point Improvement 24% (n=279) vs 4.5% (n=88) placebo @ 8wk
event count · % of participants
NCT03308799 · Phase 3 · Psoriasis · phase 3 · converted to % from 67 Count of participants as posted
PASI 52.3% (n=279) vs 25.7% (n=88) placebo @ 8wk
percent change · % of baseline
NCT03308799 · Phase 3 · Psoriasis · phase 3
show 1 more result
-67.5% (n=213) vs -11.7% (n=68) placebo @ 8wk
NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3

Calcipotriene/Betamethasone Dipropionate Foam

Nail Thickness Improvement 66.7% (n=3) @ 24wk
event count · % of participants
No placebo or comparator arm
NCT04227288 · Phase 4 · registry result, not featured evidence · converted to % from 2 Participants who experienced improvement as posted
mNAPSI 18 Fingernails @ 24wk
absolute change · Fingernails
No placebo or comparator arm
NCT04227288 · Phase 4 · registry result, not featured evidence
IGA-TS 21.1% (n=19) vs 0% (n=5) placebo @ 4wk
responder rate · % of participants
NCT03506477 · Phase 4 · registry result, not featured evidence · converted to % from 4 Participants as posted
show 1 more result
15.8% (n=19) vs 0% (n=5) placebo @ 8wk*
NCT03506477 · Phase 4 · registry result, not featured evidence · converted to % from 3 Participants as posted
PASI 75 63.2% (n=19) vs 0% (n=5) placebo @ 4wk
responder rate · % of participants
NCT03506477 · Phase 4 · registry result, not featured evidence · converted to % from 12 Participants as posted
show 1 more result
57.9% (n=19) vs 20% (n=5) placebo @ 8wk*
NCT03506477 · Phase 4 · registry result, not featured evidence · converted to % from 11 Participants as posted
PSSI 75 36.8% (n=19) vs 20% (n=5) placebo @ 2wk
responder rate · % of participants
NCT03506477 · Phase 4 · registry result, not featured evidence · converted to % from 7 Participants as posted
show 2 more results
42.1% (n=19) vs 20% (n=5) placebo @ 4wk*
NCT03506477 · Phase 4 · registry result, not featured evidence · converted to % from 8 Participants as posted
47.4% (n=19) vs 40% (n=5) placebo @ 8wk*
NCT03506477 · Phase 4 · registry result, not featured evidence · converted to % from 9 Participants as posted
ScPGA 0/1 54.5% (n=11) vs 0% (n=4) placebo @ 4wk
responder rate · % of participants
NCT03506477 · Phase 4 · registry result, not featured evidence · converted to % from 6 Participants as posted
show 1 more result
18.2% (n=11) vs 25% (n=4) placebo @ 8wk*
NCT03506477 · Phase 4 · registry result, not featured evidence · converted to % from 2 Participants as posted
Itch NRS 3.6 vs 1.3 placebo score @ 2wk
absolute value · score
NCT03506477 · Phase 4 · registry result, not featured evidence
show 2 more results
3.1 vs 3.2 placebo score @ 4wk
NCT03506477 · Phase 4 · registry result, not featured evidence
2.6 vs 2.8 placebo score @ 8wk
NCT03506477 · Phase 4 · registry result, not featured evidence
PtGA 0 1 31.6% (n=19) vs 20% (n=5) placebo @ 4wk
responder rate · % of participants
NCT03506477 · Phase 4 · registry result, not featured evidence · converted to % from 6 Participants as posted
show 1 more result
31.6% (n=19) vs 20% (n=5) placebo @ 8wk*
NCT03506477 · Phase 4 · registry result, not featured evidence · converted to % from 6 Participants as posted
DLQI -4.4 vs -11.3 placebo score @ 2wk
absolute change · score
NCT03506477 · Phase 4 · registry result, not featured evidence
show 5 more results
-6.5 vs -6.8 placebo score @ 4wk
NCT03506477 · Phase 4 · registry result, not featured evidence
-6.4 vs -7.2 placebo score @ 8wk
NCT03506477 · Phase 4 · registry result, not featured evidence
2 vs 5 placebo score @ 4wk
NCT03441789 · Phase 4 · registry result, not featured evidence · combination
5 vs 5 placebo score @ 12wk
NCT03441789 · Phase 4 · registry result, not featured evidence · combination
3 vs 6 placebo score @ 16wk
NCT03441789 · Phase 4 · registry result, not featured evidence · combination
Target Lesion Area Change Cm2 16 cm @ 2wk
absolute change · cm
No placebo or comparator arm
NCT03848871 · Phase 4 · registry result, not featured evidence
show 1 more result
10 cm @ 4wk
NCT03848871 · Phase 4 · registry result, not featured evidence
BSA 9.2% (n=20) @ 2wk
absolute change · percentage points
No placebo or comparator arm
NCT03848871 · Phase 4 · registry result, not featured evidence
show 1 more result
6.9% (n=20) @ 4wk
NCT03848871 · Phase 4 · registry result, not featured evidence
PASI 75 50% (n=14) vs 14.3% (n=14) placebo @ 16wk
responder rate · % of participants
NCT03441789 · Phase 4 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
show 2 more results
50% (n=14) vs 7.1% (n=14) placebo @ 4wk*
NCT03441789 · Phase 4 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
28.6% (n=14) vs 14.3% (n=14) placebo @ 12wk*
NCT03441789 · Phase 4 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted

+ 1 further endpoint in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Calcipotriene/Betamethasone Dipropionate Cream's landscape · Calcipotriene/Betamethasone Dipropionate Foam's landscape